plateaued on tirzepatide GLP-1 medications and weight loss plateaus Mounjaro plateau: why weight loss

In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased

Both medications are approved for use in adults, but only metformin is available for use in children 10 years and older

These effects are temporary, however

This dual agonist approach produces both the appetite suppression associated with GLP-1 activation and additional metabolic benefits associated with GIP receptor activation

Missing shipment tracking or storage guidance is another red flag

What we know Over 68 weeks, the safety profile remained stable